Business Segments · Research expenses
Business Segments — Research expenses
Vertex Pharmaceuticals Business Segments — Research expenses increased by 1.2% to $205M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 0.5%, from $206.1M to $205M. Over 3 years (FY 2022 to FY 2025), Business Segments — Research expenses shows an upward trend with a 9.7% CAGR.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2022
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase suggests a commitment to long-term innovation, though it may temporarily reduce current profitability.
Detailed definition
Costs incurred for early-stage discovery and basic research activities aimed at identifying new drug candidates. These i...
Peer comparison
Commonly reported as 'Research and Development' (R&D) expenses in the industry.
Metric ID:
vrtx_segment_pharmaceuticals_research_expensesHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $156.68M | $156.68M | $156.68M | $156.68M | $176.4M | $176.4M | $176.4M | $176.4M | $196.1M | $207.3M | $193.8M | $207.3M | $206.1M | $209.3M | $210M | $202.5M | $205M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +12.6% | +0.0% | +0.0% | +0.0% | +11.2% | +5.7% | -6.5% | +7.0% | -0.6% | +1.6% | +0.3% | -3.6% | +1.2% |
| YoY Change | — | — | — | — | +12.6% | +12.6% | +12.6% | +12.6% | +11.2% | +17.5% | +9.9% | +17.5% | +5.1% | +1.0% | +8.4% | -2.3% | -0.5% |
Range$156.68M – $210M
CAGR+7.0%
Avg YoY Growth+9.1%
Median YoY Growth+11.2%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's business segments — research expenses?
- Vertex Pharmaceuticals (VRTX) reported business segments — research expenses of $205M in Q1 2026.
- How has Vertex Pharmaceuticals's business segments — research expenses changed year-over-year?
- Vertex Pharmaceuticals's business segments — research expenses decreased by 0.5% year-over-year, from $206.1M to $205M.
- What is the long-term trend for Vertex Pharmaceuticals's business segments — research expenses?
- Over 3 years (2022 to 2025), Vertex Pharmaceuticals's business segments — research expenses has grown at a 9.7% compound annual growth rate (CAGR), from $626.7M to $827.9M.
- What does business segments — research expenses mean?
- Spending on early-stage scientific research to discover new potential medicines.